Unknown

Dataset Information

0

Tetravalent Dengue Vaccine Reduces Symptomatic and Asymptomatic Dengue Virus Infections in Healthy Children and Adolescents Aged 2-16 Years in Asia and Latin America.


ABSTRACT: Asymptomatic dengue virus-infected individuals are thought to play a major role in dengue virus transmission. The efficacy of the recently approved quadrivalent CYD-TDV dengue vaccine against asymptomatic dengue virus infection has not been previously assessed.We pooled data for 3 736 individuals who received either CYD-TDV or placebo at 0, 6, and 12 months in the immunogenicity subsets of 2 phase 3 trials (clinical trials registration NCT01373281 and NCT01374516). We defined a seroconversion algorithm (ie, a ?4-fold increase in the neutralizing antibody titer and a titer of ?40 from month 13 to month 25) as a surrogate marker of asymptomatic infection in the vaccine and placebo groups.The algorithm detected seroconversion in 94% of individuals with a diagnosis of virologically confirmed dengue between months 13 and 25, validating its discriminatory power. Among those without virologically confirmed dengue (n = 3 669), 219 of 2 485 in the vaccine group and 157 of 1 184 in the placebo group seroconverted between months 13 and 25, giving a vaccine efficacy of 33.5% (95% confidence interval [CI], 17.9%-46.1%) against asymptomatic infection. Vaccine efficacy was marginally higher in subjects aged 9-16 years (38.6%; 95% CI, 22.1%-51.5%). The annual incidence of asymptomatic dengue virus infection in this age group was 14.8%, which was 4.4 times higher than the incidence for symptomatic dengue (3.4%).The observed vaccine efficacy against asymptomatic dengue virus infections is expected to translate into reduced dengue virus transmission if sufficient individuals are vaccinated in dengue-endemic areas.

SUBMITTER: Olivera-Botello G 

PROVIDER: S-EPMC5021228 | biostudies-literature | 2016 Oct

REPOSITORIES: biostudies-literature

altmetric image

Publications

Tetravalent Dengue Vaccine Reduces Symptomatic and Asymptomatic Dengue Virus Infections in Healthy Children and Adolescents Aged 2-16 Years in Asia and Latin America.

Olivera-Botello Gustavo G   Coudeville Laurent L   Fanouillere Karen K   Guy Bruno B   Chambonneau Laurent L   Noriega Fernando F   Jackson Nicholas N  

The Journal of infectious diseases 20160714 7


<h4>Background</h4>Asymptomatic dengue virus-infected individuals are thought to play a major role in dengue virus transmission. The efficacy of the recently approved quadrivalent CYD-TDV dengue vaccine against asymptomatic dengue virus infection has not been previously assessed.<h4>Methods</h4>We pooled data for 3 736 individuals who received either CYD-TDV or placebo at 0, 6, and 12 months in the immunogenicity subsets of 2 phase 3 trials (clinical trials registration NCT01373281 and NCT013745  ...[more]

Similar Datasets

| S-EPMC5854020 | biostudies-literature
| S-EPMC4504002 | biostudies-literature
| S-EPMC7295445 | biostudies-literature
| S-EPMC8442794 | biostudies-literature
| S-EPMC10077010 | biostudies-literature
| S-EPMC3376807 | biostudies-literature
| S-EPMC5221820 | biostudies-literature
| S-EPMC8890758 | biostudies-literature
| S-EPMC9881745 | biostudies-literature
| S-EPMC6915707 | biostudies-literature